All News

1 November 2007

Seattle Genetics and MedImmune Expand Antibody-Drug Conjugate CollaborationAntibodies

30 October 2007

Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 AntibodyAntibodies

29 October 2007

Peptech successfully completes Phase I trial for PN0621Antibodies

26 October 2007

Arius announces new findings in Trop-2 and CD59 CANCER antibody programsAntibodies

26 October 2007

Novel Alternative Approach to Inhibiting Insulin Growth Factor (IGF) May Provide New Treatment for Breast Cancer and Other CancersAntibodies

25 October 2007

CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic MelanomaAntibodies

25 October 2007

Seattle Genetics Reports Preclinical Data on SGN-40 and an Anti-CD19 Antibody-Drug ConjugateAntibodies

25 October 2007

ImmunoGen, Inc. Reports New Clinical and Preclinical Data at AACR-NCI-EORTCAntibodies

25 October 2007

Milatuzumab Showed Promising Therapeutic Effects Alone and Combined With CD20 Antibody in Preclinical StudiesAntibodies

25 October 2007

Human Genome Sciences presents new data showing anti-tumor activity and safety of trail receptor antibodies in combination with chemotherapyAntibodies

24 October 2007

ARIUS announces cancer stem cell antibody program successfully completes first toxicology studyAntibodies

24 October 2007

Phase I results announced for R1507 from Genmab’s Collaboration with RocheAntibodies

24 October 2007

GlaxoSmithKline And Tolerx Form Worldwide Collaboration For Development And Commercialization Of Novel MedicationAntibodies

24 October 2007

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC ConferenceAntibodies

20 October 2007

BioWa Announces Licensing of POTELLIGENT(R) Technology by GlaxoSmithKline (GSK)Antibodies

19 October 2007

Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic LeukemiaAntibodies

19 October 2007

Lilly and MacroGenics Announce Licensing and Collaboration AgreementAntibodies

18 October 2007

Abbott Scientists Create One Molecule With Two Antibody FunctionsAntibodies

18 October 2007

Merck Serono Announces Joint Agreement with ImClone and Bristol-Myers Squibb for Erbitux in JapanAntibodies

17 October 2007

ImmunoGen, Inc. Earns Milestone with Start of SAR3419 Clinical TestingAntibodies

17 October 2007

Scientists Show Monoclonal Antibody Leads to Repair of Myelin Sheath in Laboratory Study of Multiple SclerosisAntibodies

16 October 2007

Medimmune and Crucell announce collaboration to develop new antibodies for the treatment and prevention of hospital-acquired bacterial infectionAntibodies

16 October 2007

Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple SclerosisAntibodies

16 October 2007

Bradmer provides Phase III Neuradiab trial update and guidanceAntibodies

12 October 2007

WILEX’ second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCANAntibodies

12 October 2007

Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta TherapyAntibodies

12 October 2007

Genmab Amends HuMax-CD4 Pivotal Study in CTCLAntibodies

9 October 2007

MorphoSys Enters Therapeutic Research Collaboration on Novel Target Molecule with Genesis ResearchAntibodies

6 October 2007

Argenes initiates Phase I clinical study of ARG098 (anti-Fas IgM monoclonal antibody), a novel therapeutics for rheumatoid arthritis, in EuropeAntibodies

6 October 2007

New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine’s Anti-PS Technology PlatformAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

FcRn Inhibitors Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

PSMA-Targeted Therapy Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective